YOLFTbeta
Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

ADPT · NASDAQ · Healthcare / Diagnostics & Research

29.04USD-0.44 (-1.49%)

Price History

Full chart

Market Stats

Previous Close29.48
Open29.69
Day Range28.39 – 29.78
52-Week Range12.00 – 29.96
Volume2.06M
Market Cap4.72B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.42
Dividend Yield0.00%
Beta2.10
50-Day Avg24.84
200-Day Avg18.26

About

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Chad M. Robins M.B.A.
  • Employees624
  • Headquarters1165 Eastlake Avenue East, Seattle, WA, United States, 98109, USA
  • Websitehttps://www.adaptivebiotech.com

Leadership

  • Mr. Chad M. Robins M.B.A.Co-Founder, CEO & Chairman · b. 1975
  • Ms. Julie RubinsteinPresident & COO · b. 1972
  • Mr. Kyle PiskelVP, CFO & Principal Accounting Officer · b. 1984
  • Ms. Susan BobulskyChief Commercial Officer of MRD · b. 1981
  • Mr. Christopher Carlson Ph.D.Founder
  • Ms. Karina CalzadillaVP of Investor Relations and FP&A
  • Ms. Clarice McCauleyHead of Legal, Corporate Secretary, VP & Chief Compliance Officer
  • Mr. Francis T. LoChief People Officer · b. 1981
  • Dr. Sharon Benzeno Ph.D.Chief Commercial Officer of Immune Medicine · b. 1974
  • Ms. Mary Pat LancelottaSenior Vice President of MRD BioPharma

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue38.45M55.66M85.07M98.38M154.34M185.31M170.28M178.96M276.98M
Growth (%)-+44.77%+52.83%+15.65%+56.88%+20.06%-8.11%+5.10%+54.77%
Cost of Revenue15.68M19.67M22.27M22.53M49.30M57.91M75.55M72.08M71.36M
Gross Profit22.77M35.99M62.80M75.85M105.04M127.40M94.72M106.88M205.62M
Gross Margin59.22%64.67%73.82%77.10%68.06%68.75%55.63%59.72%74.24%
Operating Expense67.24M85.75M141.19M228.67M314.01M327.58M321.76M269.43M262.74M
Operating Income-44.48M-49.76M-78.39M-152.82M-208.97M-200.19M-227.03M-162.55M-57.12M
Operating Margin-115.68%-89.39%-92.15%-155.33%-135.39%-108.03%-133.33%-90.83%-20.62%
EBITDA-37.84M-43.76M-70.60M-144.34M-193.34M-175.21M-189.27M-128.76M-29.85M
EBITDA Margin-98.42%-78.61%-82.99%-146.72%-125.27%-94.55%-111.16%-71.95%-10.78%
Net Income-42.83M-46.45M-68.61M-146.23M-207.28M-200.19M-225.25M-159.49M-59.50M
Net Income Margin-111.40%-83.44%-80.65%-148.63%-134.30%-108.03%-132.29%-89.12%-21.48%
R&D32.00M39.16M70.70M116.07M142.34M141.76M122.12M102.95M93.77M
R&D as % of Total Revenue83.22%70.35%83.11%117.98%92.22%76.50%71.72%57.53%33.85%
Interest Expense00001.67M4.24M13.80M11.58M11.78M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%1.08%2.29%8.10%6.47%4.25%

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets362.49M332.69M912.30M1.12B923.34M856.62M661.13M539.38M512.74M
Total Liabilities587.11M590.80M341.26M373.15M319.24M392.52M352.86M336.89M287.74M
Total Equity-224.62M-258.11M571.04M743.27M603.99M464.17M308.40M202.71M218.79M
Cash85.31M55.03M96.58M123.44M139.06M90.03M65.06M47.92M70.50M
Total Debt561.67M561.19M36.61M107.86M111.74M108.00M98.77M89.39M280.58M
Net Debt476.37M506.16M-59.97M-15.57M-27.32M17.97M33.71M41.47M210.09M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-34.86M-32.26M205.40M-149.68M-192.73M-183.94M-156.32M-95.21M-45.99M
Investing Cash Flow36.43M736.00K-481.70M-117.04M181.21M2.90M129.65M77.79M37.95M
Financing Cash Flow50.03M1.25M319.92M293.59M27.15M132.26M2.25M241.00K30.40M
Capital Expenditure2.51M6.32M11.20M18.80M61.75M16.35M10.70M3.66M2.96M
Free Cash Flow-37.36M-38.58M194.20M-168.49M-254.47M-200.29M-167.02M-98.88M-48.95M
Dividends Paid00-------
FCF to OCF107.19%119.59%94.55%112.56%132.04%108.89%106.84%103.85%106.43%
Dividend Paid to FCF0.00%0.00%-------

Earnings

Report DateJun 27, 2019Aug 13, 2019Nov 12, 2019Feb 26, 2020May 12, 2020Aug 10, 2020Nov 10, 2020Feb 24, 2021May 5, 2021Aug 4, 2021Nov 3, 2021Feb 15, 2022May 4, 2022Aug 3, 2022Nov 3, 2022Feb 14, 2023May 3, 2023Aug 2, 2023Nov 9, 2023Feb 14, 2024May 7, 2024Aug 1, 2024Nov 7, 2024Feb 11, 2025May 1, 2025Aug 5, 2025Nov 5, 2025Feb 5, 2026May 5, 2026Jul 29, 2026Nov 4, 2026
EPS Estimate0.00-0.14-0.22-0.20-0.21-0.28-0.28-0.29-0.40-0.41-0.43-0.45-0.45-0.43-0.38-0.35-0.37-0.35-0.34-0.33-0.34-0.33-0.27-0.24-0.31-0.24-0.16-0.18-0.16-0.13-0.10
EPS Actual-0.18-0.13-0.11-0.17-0.25-0.26-0.27-0.33-0.29-0.35-0.40-0.43-0.44-0.37-0.32-0.28-0.40-0.33-0.35-0.30-0.32-0.29-0.22-0.23-0.20-0.17-0.15-0.09-0.13-0.10-
Surprise-7.14%50.00%15.00%-19.05%7.14%3.57%-13.79%27.50%14.63%6.98%4.44%2.22%13.95%15.79%20.00%-8.11%5.71%-2.94%9.09%5.88%12.12%18.52%4.17%35.48%29.17%6.25%50.00%18.75%23.08%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap4.72B
Enterprise Value4.52B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales15.32
Price / Book31.15
EPS-0.42
Book Value0.898
Revenue (TTM)308.08M
Gross Profit (TTM)144.62M
EBITDA-21.33M
Profit Margin-20.73%
Operating Margin-22.04%
Return on Equity-38.76%
Return on Assets-4.12%
Shares Outstanding159.60M
Shares Float125.48M
Beta2.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 8 analystsTarget 26.36
  • Strong Buy
    3
  • Buy
    4
  • Hold
    1

Ownership Breakdown

Institutions
99.42%
Insiders
1.29%
Retail / Other
0.00%

Top Institutional Holders

  • Viking Global Investors LP
    29.99M4.70%
  • BlackRock Inc
    13.30M2.08%
  • Vanguard Capital Management, LLC
    6.09M0.95%
  • Wellington Management Company LLP
    5.91M0.93%
  • D. E. Shaw & Co LP
    4.63M0.72%
  • Vanguard Portfolio Management, LLC
    4.49M0.70%
  • Amvescap Plc.
    4.45M0.70%
  • Westfield Capital Management Company, L.P.
    4.27M0.67%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    4.85M3.04%
  • iShares Russell 2000 ETF
    3.92M2.46%
  • ARK Genomic Revolution ETF
    1.88M1.18%
  • Vanguard Small Cap Index
    1.75M1.10%
  • iShares Russell 2000 Growth ETF
    1.44M0.90%
  • Lord Abbett Developing Growth A
    1.19M0.75%
  • iShares Biotechnology ETF
    1.16M0.72%
  • Invesco Main Street Small Cap R6
    1.12M0.70%
  • T. Rowe Price Integrated US Sm Gr Eq
    1.10M0.69%
  • BNP Paribas US Small Cap ClassicC
    1.07M0.67%
  • BNP Paribas Health Cr Innovtr Cl Cap
    1.01M0.63%
  • Vanguard MStar Small Cap Growth Indx Inv
    1.00M0.63%